Clinical Validation of the geneType™ Ovarian Cancer Risk Prediction Model

Highlights

- **Independent validation: The geneType™ ovarian cancer risk model has been independently validated in the large, long-running Nurses' Health Study, using data entirely separate from that used to develop the original model.**
- **Integrated risk model: The study confirms that combining clinical risk factors, family history, and a polygenic risk score more effectively identifies two times more women at elevated ovarian cancer risk than using clinical or genetic information alone.**
- **Supports commercial adoption: This second major validation, following the earlier UK Biobank study, further demonstrates geneType's real-world clinical utility and underpins the Company's broader multi-cancer risk assessment strategy.**

Melbourne, Australia, 1st December 2025: Rhythm Biosciences Ltd ('**RHY**', the '**Company**' or the '**Group**') (**ASX:RHY**), a transformative, predictive cancer diagnostics technology company, is pleased to announce the publication of a peer-reviewed manuscript titled "*Validation of a clinical and polygenic risk prediction model for ovarian cancer in the Nurses' Health Study*" in Cancer Prevention Research[1]. The study confirms the performance of the Company's geneType™ Ovarian Cancer risk-prediction model in an independent, high-quality patient cohort.

This newly published study cross-validated Rhythm's geneType™ Ovarian Cancer risk-prediction model in Harvard's Nurses' Health Study[2], a well-established population cohort established in 1976 and has over 275,000 participants. Using a small, nested case control subset, results show that geneType™ can meaningfully separate women into different risk levels using a combination of clinical information, family history, and polygenic risk. The findings show that geneType™ can identify twice as many women at higher-than-average risk compared to a clinical model alone; these data reinforce earlier results from the UK Biobank analysis (Dite et al 2023[3]), demonstrating consistent performance across two independent, large-scale datasets. This provides strong evidence supporting the model's potential use in clinical practice.

Ovarian cancer is often diagnosed late and due to the lack of effective general-population screening test and as such, accurate risk prediction plays a critical role in early detection and prevention. Identifying women at higher risk enables more personalised medical discussions—including closer monitoring or consideration of preventive options. These results support geneType's role in enabling risk-stratified screening and prevention, a key approach as healthcare systems move toward more personalised and proactive disease management. The Company's commercial strategy involves making this product available to those women who are at heightened risk for ovarian cancer or are seeking

additional personal information on their disease risks. Dr Erika Spaeth, Director of Clinical Affairs, said: "Our team was honoured to work with esteemed collaborators to cross-validate the model in a cohort such as the Nurses' Health Study. This publication represents an important step in strengthening the clinical evidence behind our ovarian cancer risk prediction model."

Notes:

[1]https://pubmed.ncbi.nlm.nih.gov/41215703/

[2] https://nurseshealthstudy.org/

[3]Dite GS, Spaeth E, Murphy NM, Allman R. A combined clinical and genetic model for predicting risk of ovarian cancer. Eur J Cancer Prev. 2023 Jan 1;32(1):57-64. doi: 10.1097/CEJ.0000000000000771. Epub 2022 Oct 27. PMID: 36503897; PMCID: PMC9746333.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.